Pharma and healthcare: sector news on Saturday 14 November 2026
Average tone +4.4 (positive) across 4 companies with relevant coverage, from 66 stories.
How to read a score. Each score rates how good or bad the news was for the company, from −10 (clearly bad) to +10 (clearly good). 0 is neutral, and anything beyond ±6 is strong and rare. It rates the coverage, not the share price.
Company by company
| Company | Tone | Stories | What the coverage was about |
|---|---|---|---|
| AstraZeneca | +5.5 | 39 | Coverage was dominated by regulatory wins, with US approval of the Imfinzi bladder cancer regimen and a positive EU committee opinion on baxdrostat (Baxfendy). |
| GSK | +9.2 | 20 | Coverage was dominated by a positive European regulatory opinion for GSK's Bexsero meningitis B booster, with further support from a Dutch court finding that BioNTech infringed a GSK vaccine patent. |
| Haleon | +3.0 | 6 | Coverage was a mix of a marketing award win, an AI project to predict dengue outbreaks, and several valuation pieces. |
| Smith & Nephew | 0.0 | 1 | The only relevant coverage was a piece about the company's share price movement within the FTSE 350, with no clear direction or cause given in the headline. |
| Convatec | — | 0 |
Strongest stories in the sector
- +10.0 Company's own notice of new US approval.
- +10.0 US regulator approved bladder cancer treatment.
- +10.0 Regulatory clearance of new bladder cancer combination expands product use.
- +10.0 European committee recommends approval of new blood pressure drug.
- +10.0 Regimen gains US approval in bladder cancer.
- +10.0 Approval for patients unable to take cisplatin widens use.
- +10.0 Company announcement of US approval for new Imfinzi regimen.
- +10.0 Favourable EU opinion for its meningitis vaccine booster.
- +10.0 Favourable EU opinion for its meningitis B vaccine booster.
- +10.0 Favourable European regulatory opinion for its meningitis vaccine booster.
- +10.0 European regulator panel backs booster dose for its meningitis vaccine.
- +10.0 Regulatory announcement of favourable opinion for vaccine booster.
Pharma and healthcare: every day · FTSE 100 overview for the day
Follow by email
A short, free morning email on how the news treated the Pharma and healthcare sector: the tone, the stories behind it, and when coverage starts to turn. Launching soon; one click to unsubscribe.